Bill Ackman Eyes New Fund to Bet Against Market Complacency 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
VANCOUVER, British Columbia, Jan. 27, 2016 -- AbCellera, a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today announced a new collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to generate antibodies against an undisclosed disease target.
“Our platform has the potential to generate functional antibodies against extremely difficult targets that have been intractable until now,” says Dr. Carl Hansen, President and CEO of AbCellera. “We’re excited to partner with a global innovator like Merck in the discovery of antibodies to advance their pipeline of next-generation therapies.”
“Merck recognizes the innovative science and synergy of collaboration in British Columbia. Our company has established several life sciences collaborations in the province aimed at translating breakthrough science into products that can bring meaningful improvements to patients' lives,” explained Chirfi Guindo, President and Managing Director at Merck Canada Inc. “We are pleased to be working with AbCellera to identify novel antibodies using their innovative microfluidic discovery technology.”
Under the agreement, AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function. The agreement grants Merck the option to develop antibody candidates identified through the collaboration for specified therapeutic applications. Financial terms of the deal were not disclosed.
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera’s lead technology is a proprietary single cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans. For more information, please visit www.abcellera.com
Contact Kevin Heyries Telephone: 604.827.4151 Email: [email protected]
